. Author manuscript; available in PMC: 2019 Aug 14.

Published in final edited form as: Pediatr Blood Cancer. 2017 Sep 22;65(1):10.1002/pbc.26754. doi: 10.1002/pbc.26754

TABLE 3.

cRIT results in 42 patients

Characteristics		Median (range) or N (%)
Median CSF dose (cGy/mCi) by sampling		47.9 (14.8–207.6)
Median blood dose (cGy/mCi) by sampling	(N = 41)	1.6 (0.1–9.2)
Median total CSF dose by sampling (cGy)		1,453 (350.0–2,784)
Evaluated with	¹²⁴I–3F8 PET	19 (45%)
	¹³¹I-3F8SPECT	23 (55%)
Median ventricular dose ¹²⁴I-3F8 PET (cGy/mCi)	(N = 15)	31.1 (13.6–177.0)
Median ventricular dose ¹³¹I–3F8SPECT (cGy/mCi)	(N = 21)	89.2 (21.7–222.0)
Median thoracic spine dose ¹²⁴I-3F8 PET (cGy/mCi)	(N = 17)	17.2 (7.2–57.0)
Median thoracic spine dose ¹³¹I–3F8SPECT (cGy/mCi)	(N = 22)	19.6 (8.4–89.6)
Patients receiving 4 cRIT injections	Yes	18 (43%)
Post-cRIT response	Stable	25 (60%)
	Progressive disease	17 (41%)

Numbers represent frequencies with percentage in parentheses unless otherwise specified.